Outcome of COVID-19 in Kidney Transplant Recipients Through the SARS-CoV-2 Variants Eras: Role of Anti-SARS-CoV-2 Monoclonal Antibodies

Papadimitriou‐Olivgeris, Matthaios; Cipriano, Ana; Guggisberg, Nicolas; Kroemer, Marie; Tschopp, Jonathan; Manuel, Oriol; Golshayan, Déla

doi:10.3389/ti.2022.10721

Cited by 6 publications

(5 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1 presents the flow diagram of the study selection process, which was based on the title, abstract, and full text of each study. After eliminating duplicates from the initial 182 records, a total of 10 studies [ 4 , 8 - 11 , 15 - 19 ], including 1,569 patients, were included in the meta-analysis. All incorporated studies were retrospective in design.…”

Section: Resultsmentioning

confidence: 99%

Sotrovimab in solid organ transplant recipients with COVID-19: a systematic review and meta-analysis

Amani,

Shabestan,

Rajabkhah

et al. 2023

Korean J Transplant

View full text Add to dashboard Cite

Background Despite widespread implementation of vaccination against coronavirus disease 2019 (COVID-19), solid organ transplant recipients (SOTRs) can remain particularly vulnerable to this disease. The present study was conducted to investigate the efficacy and safety of sotrovimab in the treatment of SOTRs with COVID-19. Methods A search was performed of PubMed, Cochrane Library, Web of Science, medRxiv, and Google Scholar to gather relevant evidence through July 25, 2023. The quality of the included studies was assessed using the risk of bias tool. Comprehensive Meta-Analysis software (ver. 3.0, Biostat) was employed for data analysis. Results Ten studies, involving a total of 1,569 patients, were included. The meta-analysis revealed significant differences between the patients administered sotrovimab and those treated with the standard of care. These differences were observed in mortality rate (odds ratio [OR], 0.15; 95% confidence interval [CI], 0.03–0.67), hospitalization rate (OR, 0.35; 95% CI, 0.21–0.57), intensive care unit (ICU) admission rate (OR, 0.16; 95% CI, 0.04–0.62), the need for supplemental oxygen therapy (OR, 0.22; 95% CI, 0.09–0.51), and the need for mechanical ventilation (OR, 0.09; 95% CI, 0.01–0.70). However, no significant difference was observed between sotrovimab and other treatments regarding the rates of hospitalization or ICU admission (P>0.05). Regarding safety, sotrovimab was associated with a lower rate of adverse events compared to the absence of sotrovimab (OR, 0.15; 95% CI, 0.02–0.86). Conclusions These results suggest that sotrovimab may improve efficacy outcomes among SOTRs with COVID-19. Nevertheless, additional high-quality trials are necessary to confirm these findings.

show abstract

Section: Resultsmentioning

confidence: 99%

Sotrovimab in solid organ transplant recipients with COVID-19: a systematic review and meta-analysis

Amani,

Shabestan,

Rajabkhah

et al. 2023

Korean J Transplant

View full text Add to dashboard Cite

show abstract

“…COVID-19-related hospitalization among transplant recipients markedly decreased after the BA.1 wave, likely owing to changing population immunity, 4 improved therapeutics, 5 home testing access, and/or differing viral pathogenicity. 6 Limitations include sampling and recall bias due to observational study design, lack of SARS-CoV-2 sequencing or longitudinal testing frequency, and incomplete death ascertainment.…”

Section: Discussionmentioning

confidence: 99%

Incident COVID-19 and Hospitalizations by Variant Era Among Vaccinated Solid Organ Transplant Recipients

Chiang,

Abedon,

Alejo

et al. 2023

JAMA Netw Open

View full text Add to dashboard Cite

show abstract

“…In a retrospective study by Klein et al in 95 KTRs, monoclonal antibodies were administered in 20 patients to whom there was a significant risk in hospitalizations and visits in the emergency department [ 26 ]. Another recent retrospective study on 243 KTRs aiming to describe the evolving epidemiology and outcomes of PCR-documented SARS-CoV-2 infection, the early administration of monoclonal antibodies was associated with a better outcome [ 27 ]. With regards to antiviral agents, studies on the general population have shown that they are effective in the treatment of non-hospitalized patients with COVID-19.…”

Section: Discussionmentioning

confidence: 99%

Disease Course, Management and Outcomes in Kidney Transplant Recipients with SARS-CoV-2 Infection during the Omicron-Variant Wave: A Single-Center Experience

et al. 2023

View full text Add to dashboard Cite

Background: Since December 2019, kidney transplant recipients (KTRs) have experienced a great impact of the coronavirus disease 2019 (COVID-19) pandemic, with a higher risk of morbidity and mortality compared to the general population. Preliminary data in KTRs suggest that the Omicron variant, which has been dominant since December 2021, is more infectious than the previous ones but is associated with reduced risk of severity and low lethality rates. The purpose of our study was to assess the disease course and outcomes of the SARS-CoV-2 infection in KTRs during the Omicron-surge. Methods: This retrospective study included 451 KTRs diagnosed with SARS-CoV-2 infection between 1 December 2021 and 30 September 2022. Demographic and clinical characteristics at the time of infection, vaccination data, treatment, clinical course, and outcomes were recorded and analyzed. Results: Mean age was 51.8 ± 13.7 years with a male predominance (61.2%). The majority (76.1%) were vaccinated with at least three doses of the available mRNA vaccines, although serology revealed low anti-SARS-CoV-2 antibody titers before infection (33 [3.3–1205] AU/mL). Only 6% of the patients experienced moderate–severe disease. Accordingly, there was low prevalence of adverse outcomes, such as SARS-CoV-2-related hospitalization (11.3%) and death (0.9%). Multivariate analysis revealed that only age significantly increased the risk of SARS-CoV-2-related hospitalization. Conclusions: During the Omicron wave, the clinical course of the SARS-CoV-2 infection in KTRs has substantially changed, with lower rates of moderate and severe disease and a low prevalence of adverse outcomes. Prospective clinical trials are warranted to further elucidate the evolving pathogenesis, management, and long-term outcomes of COVID-19 in such high-risk populations.

show abstract

Outcome of COVID-19 in Kidney Transplant Recipients Through the SARS-CoV-2 Variants Eras: Role of Anti-SARS-CoV-2 Monoclonal Antibodies

Cited by 6 publications

References 32 publications

Sotrovimab in solid organ transplant recipients with COVID-19: a systematic review and meta-analysis

Sotrovimab in solid organ transplant recipients with COVID-19: a systematic review and meta-analysis

Incident COVID-19 and Hospitalizations by Variant Era Among Vaccinated Solid Organ Transplant Recipients

Disease Course, Management and Outcomes in Kidney Transplant Recipients with SARS-CoV-2 Infection during the Omicron-Variant Wave: A Single-Center Experience

Contact Info

Product

Resources

About